A wide therapeutic index is the goal for all ADC developers, and whilst efficacy is undeniable, toxicity remains the single biggest factor in narrowing this window.
2023 is set to be a landmark year for lipid-based delivery technology development and the 2nd Next-Generation Lipid-Based Nanoparticle Delivery Summit re
Not only has the pandemic fuelled interest in new modalities research, but it has also triggered a renaissance of formulation approaches amongst biopharma to bring new wave of drug substances and t